Vyzulta (latanoprostene bunod) / Bausch Health, Nicox - LARVOL DELTA

From Chemistry to Clinic: A Review of Latanoprostene Bunod and Its Therapeutic Potential. (PubMed, Mini Rev Med Chem) - "In the phase III APOLLO and LUNAR trials, LBN demonstrated efficacy comparable to, and in some analyses greater than, timolol 0.5%. Overall, current evidence supports LBN as an effective and well-tolerated therapeutic option for patients with OAG or ocular hypertension. Continued improvements in synthetic methodologies may facilitate cost-effective production and broader clinical accessibility."

Journal • Cardiovascular • Glaucoma • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain

Omidenepag isopropyl (Omlonti) for glaucoma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Glaucoma • Ophthalmology

Soluble Guanylate Cyclase Modulators in Glaucoma and Ocular Fibrosis: Mechanisms, Translational Evidence, and Therapeutic Challenges. (PubMed, J Ocul Pharmacol Ther) - "Clinical evidence is strongest for NO-donating therapies such as latanoprostene bunod, whereas direct evidence for selective sGC stimulators and activators remains limited...Despite consistent mechanistic preclinical evidence, translational challenges remain, including drug delivery, tissue-specific pharmacodynamics, and limited clinical evaluation of direct sGC modulators. Further studies are needed to define the therapeutic role of selective sGC-targeted strategies in glaucoma management."

Journal • Review • Cardiovascular • Fibrosis • Glaucoma • Immunology • Ophthalmology • RHOA

A Comprehensive Review of the Clinical Evidence Comparing Benzalkonium Chloride-Preserved and Benzalkonium Chloride-Free Latanoprost in the Treatment of Primary Open-Angle Glaucoma and Ocular Hypertension. (PubMed, Clin Ophthalmol) - "Inclusion criteria were peer-reviewed clinical trials and meta-analyses comparing latanoprost with placebo or other treatments (eg. bimatoprost, travoprost, tafluprost, latanoprostene bunod)...Comparative studies indicate that latanoprost achieves a good balance between IOP reduction and tolerability compared to bimatoprost, travoprost, tafluprost, and unoprostone...Latanoprost remains a first-line therapy for POAG and OHT due to its efficacy, safety, and patient adherence. The availability of BAK-free formulations enhances its therapeutic profile, with reduced corneal toxicity making it a preferred choice for long-term glaucoma management."

Clinical • Journal • Review • Cardiovascular • Dermatology • Glaucoma • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain

SOCIODEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF LATANOPROSTENE BUNOD INITIATORS AMONG MEDICARE FEE-FOR-SERVICE PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION (ISPOR 2026) - "In this large real-world population, LBN was utilized across a range of OAG severity stages and most commonly observed among patients with baseline IOP ≤21 mmHg. This utilization pattern supports the consideration of LBN as an early therapeutic option for patients requiring effective IOP reduction, including those with normotensive glaucoma."

Clinical • Medicare • Reimbursement • US reimbursement • Cardiovascular • Glaucoma • Ophthalmology

Shifting Medicare Glaucoma Pharmacotherapy: Rising Costs and Increasing Use of New Mechanism Agents, 2019-2023 (ARVO 2026) - "Results From 2019-2023, utilization of several legacy agents declined sharply (e.g., Travatan Z from 291,097 to 7,534 claims; Combigan from 282,811 to 144,502 claims), while medications with new mechanism of action demonstrated steady growth, including Rhopressa (60,538 to 89,044 claims), Rocklatan (13,994 to 67,255 claims), and Vyzulta (21,280 to 69,308 claims)...Spending (market) shares showed parallel shifts: Lumigan decreased from 54% to 43% and Combigan from 33% to 14%, while medications with new mechanisms of action captured a growing share of total Medicare glaucoma spending – Rhopressa increasing from 7.1% to 10.7%, Rocklatan from 1.1% to 9.0%, and Vyzulta from 2.2% to 7.2%...Total spending rose nearly 50% despite declining overall utilization, underscoring the growing cost burden associated with newer, higher-cost branded agents. These findings highlight the need for cost-conscious prescribing strategies and further evaluation of affordability and access in..."

Medicare • Reimbursement • US reimbursement • Glaucoma • Ophthalmology

The neuroprotective effect of latanoprostene bunod in an model of anterior ischemic optic neuropathy in mice (ARVO 2026) - "Conclusions AION eyes treated with 0.024% LBN preserved more RGCs through up-regulation of anti-apoptotic pathway, and down-regulation of inflammatory pawthway as well as reduction of ROS and mitochondrial oxidative stress. Topical use of latanoprostene bounding with nitric oxide might serve as a potential treatment for patients with AION in the future."

IO biomarker • Preclinical • Ocular Inflammation • Ophthalmology • Optic Neuritis • BCL2 • CASP3 • GFAP • IL6 • NOS3 • NOX4

Intraocular pressure and trabecular meshwork cytoskeletal effects of latanoprost, latanoprostene bunod and latanoprost–netarsudil (ARVO 2026) - "Our results suggest that the latanoprost–netarsudil combination lowers pressure more quickly and changes the drainage tissue more than the other latanoprost-based drops. This implies that different "upgraded" latanoprost products are not interchangeable, and that pairing latanoprost with a drug that targets the drainage system may offer extra benefit for people who need better eye pressure control."

Glaucoma • Ophthalmology

Retrospective real-world evidence study of clinical outcomes and eyecare practitioner satisfaction with topical latanoprostene bunod in patients with ocular open-angle glaucoma or ocular hypertension (ARVO 2026) - "The results show that eye pressure was reduced by 28% on average from the start of the study to the patients' most recent visit to their eye doctor. The doctors reported high levels of effectiveness and overall satisfaction with LBN."

Clinical data • HEOR • Real-world • Real-world evidence • Retrospective data • Glaucoma • Ophthalmology

Effects of topical prostaglandin analogs on choroidal thickness in otherwise untreated young guinea pigs (ARVO 2026) - "Purpose We previously reported reductions in intraocular pressure (IOP) in young guinea pigs treated with both latanoprost (LP) and latanoprostene (LBN), with a slightly greater effect of the latter. Conclusions Despite the small sample size (n=3/group), untreated fellow eyes showed trends of early choroidal thinning, likely due to developmental axial elongation, with reduced thinning in LBN and LP groups, suggesting contralateral effects. The trend of relative thickening in LBN- and LP-treated eyes supports further investigation into their potential application for myopia control."

Ophthalmology

Benefit of Latanoprostene Bunod (Vyzulta) for Glaucoma Switched from Prior Pharmacotherapy: A Retrospective Cohort Study in Taiwan. (PubMed, Ophthalmol Ther) - "In this retrospective cohort of Taiwanese patients with glaucoma whose IOP remained inadequately controlled on prior PGAs therapy, switching to LBN was associated with a statistically significant, although modest, reduction in IOP over 12 months and a low rate of mild, non-serious ocular adverse events. These exploratory real-world findings provide hypothesis-generating evidence supporting LBN as a treatment option when further IOP reduction is needed and should be confirmed in larger prospective multicenter studies."

Journal • Retrospective data • Glaucoma • Ophthalmology

Investigation of the effect of latanoprostene bunod and latanoprost on peripapillary optical coherence tomography angiography. (PubMed, J Fr Ophtalmol) - "In conclusion, LBN administered once a day increased VD in peripapillary OCTA. LP had no effect on VD. Future studies should be aimed at determining whether this effect of LBN is NO induced or due to higher IOP reduction."

Clinical • Journal • Glaucoma • Ophthalmology

Different intraocular pressure-lowering effects of latanoprostene bunod across glaucoma subtypes: a 12-month real-world clinical study. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "LBN demonstrated differential IOP-lowering effects across glaucoma subtypes, with a notably enhanced effect on PXFG. This superior efficacy in PXFG, likely due to LBN's dual mechanism overcoming pseudoexfoliative outflow resistance, suggests that switching from latanoprost may help delay the need for surgical intervention in this challenging patient population."

Journal • Real-world evidence • Glaucoma • Hypotension • Ophthalmology

Angina Pectoris Following Latanoprostene Bunod 0.024% Administration: A Case Report. (PubMed, Cureus) - "Although prostaglandin analogs such as latanoprostene bunod are primarily believed to exert localized ocular effects, they may cause systemic reactions through mechanisms including vasoconstriction and nociceptor sensitization-particularly in susceptible individuals. This case underscores the importance of clinical vigilance for atypical systemic symptoms following initiation of topical glaucoma medications and supports the need for further investigation into their cardiovascular safety profile."

Journal • Cardiovascular • Gastroenterology • Glaucoma • Ophthalmology • Pain

The effect of latanoprostene bunod on retinal vessel density in patients with primary open-angle glaucoma. (PubMed, Eur J Ophthalmol) - "These vascular benefits likely result from nitric oxide (NO)-mediated microcirculatory improvements. Larger, long-term multicenter studies are needed to explore LBN's sustained vascular effects in glaucoma management."

Journal • Glaucoma • Ophthalmology

Evaluation of corneal and anterior segment alterations following short-term use of topical latanoprostene bunod. (PubMed, Int Ophthalmol) - "Short-term use of latanoprostene bunod reduced corneal densitometry values, suggesting improved corneal transparency without significantly affecting corneal thickness, endothelial cell characteristics, or anterior segment parameters. Further long-term studies with larger sample sizes are needed to evaluate its prolonged effects on corneal health."

Journal • Glaucoma • Ophthalmology

Gland Pharma ANDA used in Glaucoma treatment gets USFDA approval (CNBC-TV18) - "Gland Pharma on Wednesday, April 30, said it has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for latanoprostene bunod ophthalmic solution, 0.024%. The product is bioequivalent and therapeutically equivalent to the reference listing drug VYZULTA Opthalmic solution, 0.024% of Bausch and Lomb, Inc....As per the IQVIA, the product had US sales of around $171 million for the 12 months ending February 2025."

ANDA • Sales • Glaucoma • Ophthalmology

Latanoprostene Bunod 0.024% Early Experience Program (LEEP): A Canadian Initiative for Open-Angle Glaucoma and Ocular Hypertension. (PubMed, Ophthalmol Ther) - "This initial Canadian clinical experience of LBN in diverse patient and physician populations reflected its use in a real-world context, and demonstrated a significant IOP-lowering effect with LBN across patient groups seen in routine practice. Patient and physician satisfaction scores were high and in notable agreement."

Journal • Cardiovascular • Glaucoma • Ophthalmology

Drugs for open-angle glaucoma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Glaucoma • Ophthalmology

Corrigendum: Latanoprostene bunod: the first nitric oxide-donating antiglaucoma medication. (PubMed, Med Gas Res) - No abstract available

Journal • Glaucoma • Ophthalmology

Real-world impact of latanoprostene bunod ophthalmic solution 0.024% in glaucoma therapy: a narrative review. (PubMed, Front Ophthalmol (Lausanne)) - "LBN was generally well tolerated in real-world studies; the most common adverse events were consistent with the known safety profile of LBN. Data from real-world studies provide important insights regarding the potential effectiveness and tolerability of LBN in the clinical setting and suggest that LBN is well tolerated and associated with significant, clinically meaningful, and durable reductions in IOP."

Journal • Real-world evidence • Review • Cardiovascular • Glaucoma • Ophthalmology

Impact on intraocular pressure after switching to Latanoprostene Bunod in patients with glaucoma in real-world clinical practice (ARVO 2025) - "These large-scale real-world study findings are consistent with those observed in smaller observational studies and clinical trials, confirming LBN effectiveness in real-world clinical practice Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Real-world • Real-world evidence • Glaucoma • Ophthalmology

Latanoprostene bunod: the first nitric oxide-donating antiglaucoma medication. (PubMed, Med Gas Res) - "Latanoprostene bunod has demonstrated strong efficacy and a favorable safety profile in both clinical trials and real-world studies. Given the promising results of latanoprostene bunod and advancements in drug delivery, topical fixed-combination and sustained-release formulations containing latanoprostene bunod and other agents targeting different intraocular pressure-lowering mechanisms may become available in the future."

Journal • Review • Cardiovascular • Glaucoma • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain

Effects of 0.024% latanoprostene bunod on intraocular pressure and pupil diameter in normal cats and cats with congenital glaucoma. (PubMed, Vet Ophthalmol) - "Transient IOP reduction was observed after topical administration of LAT and LBN in FCG cats; and mean IOP difference was statistically significantly greater in LBN-treated eyes. However, the apparent enhanced hypotensive effect of LBN is not clinically significant."

Journal • Glaucoma • Ophthalmology

The Effect of Latanoprostene Bunod 0.024% on Optical Coherence Tomography Angiography in Newly Diagnosed Open Angle Glaucoma. (PubMed, J Glaucoma) - "In conclusion, treatment with LBN ophthalmic solution 0.024% reduced IOP by an average of 29.9% and 31.8% in patients with POAG and PXG, respectively, and improved VD in different quadrants in all slabs. Therefore, the importance of LBN in the treatment of glaucoma is likely to be that it increases macular microcirculation, possibly via NO, independent of its IOP-reducing effect."

Journal • Glaucoma • Ophthalmology